Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study demonstrates that bioequivalence for proposed 50-mg ritlecitinib capsules versus clinical 100-mg capsules can be supported using a PBPK model-based biowaiver, achieving over 90% probability of success.

This article reviews the Clinical Pearls presentation format introduced at the American College of Physicians' 2001 meeting for its effectiveness in applying practical clinical tips, but provides no new empirical results.

This review discusses recent developments in α1-adrenoceptor antagonists and 5α-reductase inhibitors for treating benign prostatic hyperplasia, reporting no new clinical results while identifying potential areas for future drug development.

Finasteride discontinuation increases sperm count in men.

This study developed and validated a liquid chromatography-mass spectrometry method for accurately identifying and quantifying tamsulosin and finasteride in pharmaceutical forms, showing its effectiveness for quality control.

Alpha-blocker therapy may not be needed long-term when combined with finasteride for BPH.

This study found that men with depression, erectile dysfunction, and marijuana usage were more likely to be treated for lower urinary tract symptoms, while alcohol use was not significantly associated.

This study developed and validated a gradient reversed-phase liquid chromatographic method to effectively measure Finasteride and its related impurities in pharmaceutical bulk drugs, demonstrating high linearity and precision.

This protocol outlines a planned Cochrane Review to evaluate the effects of 5-alpha-reductase inhibitors on lower urinary tract symptoms caused by benign prostatic obstruction, and it reports no new findings.

This article discusses the ethical concerns and implications of a partnership between the National Prostate Cancer Coalition and Viadur, including the perceived endorsement of a specific drug.

In this study, finasteride alone or combined with terazosin significantly reduced PSA levels in men with BPH, while terazosin alone did not affect PSA levels.

This study found no baseline factors that predicted flibanserin efficacy for HSDD, though low testosterone or use of hormonal contraceptives were associated with reduced efficacy.

In this review and meta-analysis, the authors concluded that 5α-reductase inhibitor therapy is not consistently associated with significant increases in serum testosterone levels in men.

Long-term use of a certain medication can worsen erectile function in aged rats by damaging penile muscle cells.

Taking medication for hair loss might cause sexual problems.

This study reports an increase in the use of tamsulosin/finasteride for benign prostatic syndrome in Germany but highlights that reliable comparisons with monotherapies are lacking due to study design deficiencies.

This study found that finasteride significantly reduced levodopa-induced dyskinesia in both male and female rats without diminishing l-DOPA's motor benefits, indicating potential for clinical trials in Parkinson's patients.

This article discusses the potential health risks associated with long-term use of finasteride and dutasteride for prostate and hair loss treatments, suggesting risks may include non-alcoholic fatty liver disease, insulin resistance, type 2 diabetes, and other metabolic issues.

This review of legal cases found that 5α-reductase inhibitors, alleged to cause sexual, mental, and physical side effects, have led to numerous lawsuits with increasing litigation expected in the future.

Finasteride and bicalutamide can affect blood sugar, so diabetics need monitoring.

Finasteride and bicalutamide can affect blood sugar, so diabetics need monitoring.

This study reported no significant difference in efficacy or sexual dysfunction risk between 5α-reductase inhibitors and placebo for androgenetic alopecia, suggesting that dutasteride 0.5 mg may be considered pending further research.

In this study, bicalutamide at low doses was not linked to significant liver enzyme changes compared to other androgen-blocking treatments in transfeminine adolescents and young adults, suggesting its safety with careful monitoring for this population over one year.

This study concluded that transurethral seminal vesiculoscopy combined with finasteride is a safe and effective treatment for recurrent hemospermia in the observed patients.

This review paper provides a comprehensive overview of Dutasteride, detailing its pharmacological properties, mechanisms, and therapeutic applications, particularly for androgenetic alopecia and benign prostatic hyperplasia, and discusses its potential use in prostate cancer prevention and transgender medicine.

This study suggests that 5α-reductase inhibitors do not significantly affect male reproductive function but may require caution in men with oligospermia or ejaculatory issues.

In this study, treatment with 1 mg of finasteride was associated with stable sexual function, suggesting that sexual side effects may be less common than indicated in clinical trials.